1.
Emerg Infect Dis
; 23(10)2017 10.
Article
in English
| MEDLINE
| ID: mdl-28767036
ABSTRACT
Delamanid, recently available for the treatment of multidrug-resistant tuberculosis (MDR TB), has had limited use outside clinical trials. We present the early treatment results for 53 patients from 7 countries who received a delamanid-containing treatment for MDR TB. Results show good tolerability and treatment response at 6 months.
Subject(s)
Antitubercular Agents/therapeutic use , Nitroimidazoles/therapeutic use , Oxazoles/therapeutic use , Tuberculosis, Multidrug-Resistant/drug therapy , Adolescent , Female , HIV Infections/complications , Hepatitis C/complications , Humans , Male , Retrospective Studies , Tuberculosis, Multidrug-Resistant/complications
2.
Eur Respir J
; 48(3): 938-43, 2016 09.
Article
in English
| MEDLINE
| ID: mdl-27338197